<p><strong>In the week of September 14, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars"><strong>👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</strong></a></h4><p><strong>👉 Search and filter in the largest global database</strong> with over <strong>6 000 GC, LC, MS and spectroscopy webinars</strong>.</p></blockquote><h5><strong>1. Agilent Technologies: Using Targeted Methylation Sequencing to Bring Epigenetic Biomarkers to the Clinic</strong></h5><ul><li>Mo, 14.9.2026 18:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6497">Registration</a></li></ul><p>Discover how native-read nanopore sequencing and Agilent SureSelect targeting can translate epigenetic biomarker discoveries into high-depth methylation assays for clinical research.</p><h5><strong>2. Thermo Fisher Scientific: Polymeric, porous, monodisperse particle development and application to reversed-phase separations of biological molecules</strong></h5><ul><li>Tu, 15.9.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6473">Registration</a></li></ul><p>Learn how monodisperse polymeric particle architecture can optimize reversed-phase separations of biological molecules, including oligonucleotides and RNA.</p><h5><strong>3. Waters Corporation: LC Coffee Breaks: Strategies to Identify and Reduce Carryover</strong></h5><ul><li>Tu, 15.9.2026 14:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6418">Registration</a></li></ul><p>Learn practical strategies to identify and eliminate LC carryover, including common sources, troubleshooting techniques, and proven solutions for more robust and reproducible analyses.</p><h5><strong>4. C&amp;EN: Fast Track Closed-Loop Experimentation with AI-Driven Automation on Stuntman</strong></h5><ul><li>Tu, 15.9.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6472">Registration</a></li></ul><p>Discover how the Stuntman platform integrates AI and laboratory automation to enable closed-loop experimentation and accelerate research and discovery workflows.</p><h5><strong>5. Thermo Fisher Scientific: Rethinking what's possible</strong></h5><ul><li>Tu, 15.9.2026 18:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6536">Registration</a></li></ul><p>Explore how advances in proteomics, systems biology, and computational approaches are reshaping precision health and opening new ways to study disease, biology, and One Health.</p><h5><strong>6. Thermo Fisher Scientific: LC-MS/MS determination of PFAS in wild Baltic grey seal plasma for the assessment of health and developmental parameters</strong></h5><ul><li>We, 16.9.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6474">Registration</a></li></ul><p>Learn how Hypersil GOLD C18, delay columns, isotope dilution, and LC-MS/MS support PFAS biomonitoring in wildlife plasma and assessment of health and developmental parameters.</p><h5><strong>7. SelectScience: Moving beyond reactive compliance by building inspection-ready laboratories</strong></h5><ul><li>We, 16.9.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6501">Registration</a></li></ul><p>Learn how AI and cloud-based informatics can strengthen data integrity, compliance, and inspection readiness in modern analytical laboratories.</p><h5><strong>8. Thermo Fisher Scientific: Powering Discovery at Scale</strong></h5><ul><li>We, 16.9.2026 18:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6537">Registration</a></li></ul><p>Discover how high-throughput proteomics, advanced analytical performance, and computational biology enable larger translational studies and deeper biological insights.</p><h5><strong>9. Agilent Technologies: Increasing LC/MS Productivity: Deciding Which High Throughput Solution is Right for You</strong></h5><ul><li>We, 16.9.2026 18:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6494">Registration</a></li></ul><p>Learn how to select the right high-throughput LC/MS solution for your laboratory by balancing analytical performance, throughput, and scalability.</p><h5><strong>10. Agilent Technologies: Accelerating Biopharmaceutical Development with the Agilent Cary 3500 UV-Vis Spectrophotometer</strong></h5><ul><li>Th, 17.9.2026 07:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6507">Registration</a></li></ul><p>Explore how the Agilent Cary 3500 UV-Vis spectrophotometer supports biopharmaceutical characterization from development through routine quality control.</p><h5><strong>11. Thermo Fisher Scientific: EFOX: Smarter Environmental Workflows for PFAS and Emerging Contaminants</strong></h5><ul><li>Th, 17.9.2026 08:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6508">Registration</a></li></ul><p>Discover how the Thermo Scientific EFOX platform streamlines PFAS and emerging contaminant analysis for modern environmental laboratories.</p><h5><strong>12. Thermo Fisher Scientific: Practical aspects and advantages of coupling ion exchange chromatography to mass spectrometry for biotherapeutic analysis</strong></h5><ul><li>Th, 17.9.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6475">Registration</a></li></ul><p>Learn how direct IEX-MS coupling with pH-gradient elution and volatile buffers can streamline biotherapeutic characterization.</p><h5><strong>13. Thermo Fisher Scientific: Building the Modern Pharma QA/QC Laboratory</strong></h5><ul><li>Th, 17.9.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6510">Registration</a></li></ul><p>Discover a practical roadmap for moving pharmaceutical QA/QC laboratories from legacy systems toward connected digital environments with stronger compliance and efficiency.</p><h5><strong>14. Waters Corporation: Excipients in Biopharma – Polysorbate Analysis</strong></h5><ul><li>Th, 17.9.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6509">Registration</a></li></ul><p>Learn how HPLC with charged aerosol detection simplifies characterization of Polysorbate 20 and 80 in biopharmaceutical excipient analysis.</p><h5><strong>15. SelectScience: Master EV profiling with Leprechaun – A case study from North Texas Eye Research Institute</strong></h5><ul><li>Th, 17.9.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6506">Registration</a></li></ul><p>Explore advanced extracellular vesicle profiling and discover how the Leprechaun platform streamlines EV characterization for research applications.</p><h5><strong>16. Agilent Technologies: Comprehensive SEC Solutions: Performance and Application Insights Across Agilent’s SEC Columns</strong></h5><ul><li>Th, 17.9.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6350">Registration</a></li></ul><p>Optimize size exclusion chromatography and learn how Agilent SEC columns support high-resolution aggregate analysis and polymer profiling in R&amp;D and quality control.</p><h5><strong>17. Thermo Fisher Scientific: Turning Discovery into Precision Health</strong></h5><ul><li>Th, 17.9.2026 18:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6538">Registration</a></li></ul><p>Discover how translational proteomics bridges molecular discovery and clinical implementation, accelerating biomarker development and precision health research.</p><h5><strong>18. SelectScience: High-resolution oligonucleotide analysis with capillary gel electrophoresis</strong></h5><ul><li>Fr, 18.9.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6512">Registration</a></li></ul><p>Learn how capillary gel electrophoresis delivers single-nucleotide resolution for high-resolution oligonucleotide characterization.</p><h5><strong>19. SelectScience: Reliable biopharma QC starts with MAM system readiness</strong></h5><ul><li>Fr, 18.9.2026 17:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6513">Registration</a></li></ul><p>Learn how automated LC/MS system readiness checks support reliable multi-attribute method workflows and consistent results in GMP biopharmaceutical QC environments.</p>

Webinars LabRulezLCMS Week 38/2026

ISC 2026 - Day 4

Comprehensive investigation of matrix effect evaluation approaches for reliable quantification in bioanalysis using UHPLC-MS/MS

Article

Events

Webinars

Scientific article

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

GW-501516 analysis

Targeted HPLC analysis of GW-501516 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The GW-501516 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of GW-501516 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About GW-501516</strong></h4><p>GW-501516, also known as cardarine, is a synthetic research compound that acts as a selective agonist of the peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ). Activation of this nuclear receptor regulates genes involved in fatty-acid metabolism, energy utilisation, and lipid homeostasis. Unlike SARMs, GW-501516 does not act primarily through the androgen receptor.</p><p>GW-501516 was investigated as a potential treatment for metabolic and cardiovascular disorders, including dyslipidaemia. It has not been approved for therapeutic use, and the World Anti-Doping Agency has issued a warning regarding its unauthorised sale and use among athletes.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of GW-501516</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> GW-501516</li><li><strong>Other name:</strong> Cardarine</li><li><strong>CAS number:</strong> 317318-70-0</li><li><strong>Testing method:</strong> HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders:</strong> 10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for GW-501516. It does not automatically screen the sample for other PPAR agonists, SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of GW-501516 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

LGD-3033 analysis

Targeted HPLC analysis of LGD-3033 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The LGD-3033 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of the target compound in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About LGD-3033</strong></h4><p>LGD-3033 is an orally active, non-steroidal selective androgen receptor modulator (SARM) investigated primarily in preclinical studies. It binds to the androgen receptor and has demonstrated tissue-selective anabolic activity in animal models, particularly in muscle and bone.</p><p>Preclinical research found potent activity in skeletal muscle, while its effects on androgen-sensitive tissues such as the prostate were comparatively lower at selected doses. The compound has also been investigated for its potential effects on bone density and strength.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of LGD-3033</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> LGD-3033</li><li><strong>CAS number:</strong> 917891-35-1</li><li><strong>Testing method:</strong> HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders:</strong> 10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for the stated target compound. It does not automatically screen the sample for other SARMs, related substances, contaminants, or undeclared compounds.</li><li>For oral products, the minimum amount required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><strong>Sterility Testing (TAMC/TYMC)</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

MK-677 analysis

Targeted HPLC analysis of MK-677 (ibutamoren) in pills, tablets, capsules, and raw API powders. The test confirms identity and determines content.

<p><strong>The MK-677 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of ibutamoren in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About MK-677&nbsp;</strong></h4><p>MK-677, also known as ibutamoren, is an orally active, non-peptide growth hormone secretagogue. It acts as an agonist of the ghrelin receptor and stimulates the release of growth hormone, which can subsequently increase circulating levels of insulin-like growth factor 1 (IGF-1).</p><p>MK-677 has been investigated in clinical and preclinical studies focusing on growth hormone secretion, body composition, muscle mass, bone metabolism, and conditions associated with growth hormone deficiency. It is not a selective androgen receptor modulator (SARM) and does not act primarily through the androgen receptor. MK-677 has not been approved by the FDA for therapeutic use.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of MK-677</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>MK-677</li><li><strong>Other name: </strong>Ibutamoren</li><li><strong>CAS number:</strong> 159634-47-6</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for MK-677. It does not automatically screen the sample for other growth hormone secretagogues, SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of MK-677 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

RAD-150 analysis

Targeted HPLC analysis of RAD-150 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The RAD-150 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of RAD-150 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About RAD-150</strong></h4><p>RAD-150 is a synthetic research compound commonly described as a non-steroidal selective androgen receptor modulator (SARM). It is associated with androgen receptor signalling and is marketed as a structurally modified compound related to RAD-140.</p><p>Unlike RAD-140, RAD-150 has not been adequately characterised in peer-reviewed preclinical or clinical studies. Information about its biological activity, pharmacokinetics, safety, and potential effects therefore remains limited.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of RAD-150</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>RAD-150</li><li><strong>CAS number:</strong> 1208070-53-4</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for RAD-150. It does not automatically screen the sample for RAD-140, other SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of RAD-150 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

SR-9011 analysis

Targeted HPLC analysis of SR-9011 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The SR-9011 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SR-9011 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About SR-9011</strong></h4><p>SR-9011 is a synthetic research compound commonly described as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are involved in the regulation of circadian rhythms, metabolism, sleep, and other physiological processes.</p><p>SR-9011 has been investigated mainly in preclinical and laboratory studies examining circadian regulation, cellular metabolism, inflammatory processes, and cancer-cell viability. It has not been approved for therapeutic use.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of SR-9011</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>SR-9011</li><li><strong>CAS number:</strong> 1379686-29-9</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 2 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for SR-9011. It does not automatically screen the sample for SR-9009, other REV-ERB agonists, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of SR-9011 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Bronchogen Analysis

HPLC analysis of Bronchogen for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

<p><span><strong>This analysis is designed to confirm the identity and determine the amount and peptide purity of Bronchogen in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its proportion relative to chromatographically detectable impurities.</strong></span></p><h4><span><strong>Bronchogen</strong></span></h4><p><span>Bronchogen is a synthetic <strong>tetrapeptide</strong> with the amino acid sequence <strong>Ala-Glu-Asp-Leu</strong>. Scientific studies have investigated it primarily in experimental models involving bronchial epithelium and lung tissue.</span></p><p><span>The molecule consists of only four amino acid residues. HPLC analysis confirms the presence of Bronchogen in the sample, determines its amount and evaluates peptide purity.</span></p><h4><span><strong>What the Analysis Determines</strong></span></h4><ul><li><span>Identity of Bronchogen</span></li><li><span>Amount of Bronchogen in the sample</span></li><li><span>Peptide purity</span></li><li><span>Results in a format appropriate for the submitted sample type</span></li></ul><h4><span><strong>Analysis Parameters</strong></span></h4><ul><li><span><strong>Target compound:</strong> Bronchogen</span></li><li><span><strong>Sequence:</strong> Ala-Glu-Asp-Leu</span></li><li><span><strong>Testing method:</strong> HPLC</span></li><li><span><strong>Detection limit:</strong> less than one twentieth of the usual dosage per vial</span></li><li><span><strong>Result format for lyophilizates:</strong> mg per vial and peptide purity</span></li><li><span><strong>Alternative result format:</strong> m/m purity and peptide purity</span></li><li><span><strong>Minimum lyophilizate sample:</strong> one whole unopened vial containing the lyophilizate</span></li><li><span><strong>Minimum raw API powder sample:</strong> 30 mg in a sealed glass vial to prevent moisture absorption</span></li><li><span><strong>Average turnaround time:</strong> 7 business days</span></li></ul><blockquote><h5><span><strong>Important Notice</strong></span></h5><p><span>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Bronchogen in mg per vial together with peptide purity.</span></p></blockquote><h4><span><strong>Additional Analyses</strong></span></h4><h5><span><strong>TFA Analysis</strong></span></h5><ul><li><span>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</span></li></ul><h5><span><strong>Raw Data</strong></span></h5><ul><li><span>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</span></li></ul><h5><span><strong>Fentanyl Presence Analysis</strong></span></h5><h5><span><strong>Alternative Result Format – m/m Purity</strong></span></h5><ul><li><span>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</span></li></ul><h5><span><strong>Variance Testing</strong></span></h5><ul><li><span>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</span></li></ul><h5><span><strong>pH Measurement</strong></span></h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522"><span><strong>Endotoxin Analysis</strong></span></a></h5><ul><li><span>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</span></li><li><span>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</span></li><li><span>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526"><span><strong>CHNS Mass Report</strong></span></a></h5><ul><li><span>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</span></li></ul><h5><span><strong>Additional Report</strong></span></h5><ul><li><span>A separate additional laboratory report issued under a different client name.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><span><strong>LC-MS Screening for Peptide Contamination</strong></span></a></h5><ul><li><span>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</span></li><li><span>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><span><strong>Sterility Testing</strong></span></a></h5><ul><li><span>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><span><strong>Heavy Metals Analysis</strong></span></a></h5><ul><li><span>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</span></li></ul>

Cagrilintide analysis

HPLC analysis of cagrilintide for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

<p><span><strong>This analysis is designed to confirm the identity and determine the amount and peptide purity of cagrilintide in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.</strong></span></p><h4><span><strong>Cagrilintide</strong></span></h4><p><span>Cagrilintide is a synthetic, lipidated, long-acting amylin analogue. Its molecular structure was developed to improve stability and extend its duration of action compared with native amylin. Scientific and clinical literature describes cagrilintide as an investigational peptide rather than a generally available approved active substance.</span></p><p><span>Its structure contains modified amino acid residues and an amidated C-terminus. The stated molecular weight is approximately 4,409 Da.</span></p><p><span>HPLC analysis confirms the presence of cagrilintide in the sample, determines its amount and evaluates peptide purity.</span></p><h4><span><strong>What the Analysis Determines</strong></span></h4><ul><li><span>Identity of cagrilintide</span></li><li><span>Amount of cagrilintide in the sample</span></li><li><span>Peptide purity</span></li><li><span>Results in a format appropriate for the submitted sample type</span></li></ul><h4><span><strong>Analysis Parameters</strong></span></h4><ul><li><span><strong>Target compound:</strong> cagrilintide</span></li><li><span><strong>CAS number:</strong> 1415456-99-3</span></li><li><span><strong>Molecular weight:</strong> 4,409 Da</span></li><li><span><strong>Sequence:</strong> Unk-Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Vas-Gly-Ser-Asn-Thr-Pro-NH2</span></li><li><span><strong>Testing method:</strong> HPLC</span></li><li><span><strong>Detection limit:</strong> less than one twentieth of the usual dosage per vial</span></li><li><span><strong>Result format for lyophilizates:</strong> mg per vial and peptide purity</span></li><li><span><strong>Alternative result format:</strong> m/m purity and peptide purity</span></li><li><span><strong>Minimum lyophilizate sample:</strong> one whole unopened vial containing the lyophilizate</span></li><li><span><strong>Minimum raw API powder sample:</strong> 30 mg in a sealed glass vial to prevent moisture absorption</span></li><li><span><strong>Average turnaround time:</strong> 7 business days</span></li></ul><blockquote><h5><span><strong>Important Notice</strong></span></h5><p><span>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of cagrilintide in mg per vial together with peptide purity.</span></p></blockquote><h4><span><strong>Additional Analyses</strong></span></h4><h5><span><strong>TFA Analysis</strong></span></h5><ul><li><span>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</span></li></ul><h5><span><strong>Raw Data</strong></span></h5><ul><li><span>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</span></li></ul><h5><span><strong>Fentanyl Presence Analysis</strong></span></h5><h5><span><strong>Alternative Result Format – m/m Purity</strong></span></h5><ul><li><span>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</span></li></ul><h5><span><strong>Variance Testing</strong></span></h5><ul><li><span>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</span></li></ul><h5><span><strong>pH Measurement</strong></span></h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522"><span><strong>Endotoxin Analysis</strong></span></a></h5><ul><li><span>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</span></li><li><span>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</span></li><li><span>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526"><span><strong>CHNS Mass Report</strong></span></a></h5><p><span>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</span></p><h5><span><strong>Additional Report</strong></span></h5><ul><li><span>A separate additional laboratory report issued under a different client name.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><span><strong>LC-MS Screening for Peptide Contamination</strong></span></a></h5><ul><li><span>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</span></li><li><span>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><span><strong>Sterility Testing</strong></span></a></h5><ul><li><span>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><span><strong>Heavy Metals Analysis</strong></span></a></h5><ul><li><span>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</span></li></ul>

Clomiphene analysis

Targeted HPLC analysis of clomiphene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Clomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Clomiphene&nbsp;</strong></h4><p>Clomiphene, also known by the trade name Clomid, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can exert estrogenic or anti-estrogenic effects depending on the target tissue. Clomiphene is used clinically to induce ovulation in selected patients with ovulatory dysfunction.</p><p>The compound is commonly administered as clomiphene citrate and consists of two geometric isomers, enclomiphene and zuclomiphene, which differ in their biological properties.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of clomiphene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound: </strong>Clomiphene</li><li><strong>Other name: </strong>Clomid</li><li><strong>CAS number:</strong> 911-45-5</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 5 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for clomiphene. It does not automatically screen the sample for enclomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of clomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Cagrilintide/Semaglutide (CagriSema) blend analysis

HPLC analysis of a CagriSema blend for identification and separate quantification of cagrilintide and semaglutide in mg per vial.

<p><span><strong>This analysis is designed to confirm the identity and separately determine the amount of cagrilintide and semaglutide in a combined lyophilized sample. HPLC testing measures the content of both target peptides, with results reported in mg per vial.</strong></span></p><p><span>Peptide purity cannot be reliably determined in a blend because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.</span></p><h4><span><strong>CagriSema</strong></span></h4><p><span>CagriSema refers to a combination of cagrilintide and semaglutide in a single product. <strong>Cagrilintide</strong> is a synthetic <strong>lipidated amylin analogue</strong>, while <strong>semaglutide</strong> is a modified <strong>GLP-1 peptide analogue</strong>.</span></p><p><span>Because the sample contains two different peptide components, the analysis focuses on confirming their identity and separately determining the amount of each peptide. The report therefore provides individual results for cagrilintide and semaglutide.</span></p><h4><span><strong>What the Analysis Determines</strong></span></h4><ul><li><span>Identity of cagrilintide</span></li><li><span>Identity of semaglutide</span></li><li><span>Amount of cagrilintide in the sample</span></li><li><span>Amount of semaglutide in the sample</span></li><li><span>Results in mg per vial for each target peptide</span></li></ul><h4><span><strong>Analysis Parameters</strong></span></h4><ul><li><span><strong>Target compounds:</strong> cagrilintide and semaglutide</span></li><li><span><strong>Blend name:</strong> CagriSema</span></li><li><span><strong>Testing method:</strong> HPLC</span></li><li><span><strong>Detection limit:</strong> less than one twentieth of the usual dosage per vial</span></li><li><span><strong>Result format:</strong> mg per vial for each target peptide</span></li><li><span><strong>Minimum sample amount:</strong> one whole unopened vial containing the lyophilizate</span></li><li><span><strong>Average turnaround time:</strong> 7 business days</span></li><li><span><strong>Peptide purity:</strong> not measured</span></li></ul><blockquote><h5><span><strong>Important Notice</strong></span></h5><p><span>Peptide purity cannot be determined for a cagrilintide/semaglutide blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.</span></p><p><span>The final report provides identification and separately measured amounts of cagrilintide and semaglutide. Peptide purity is not included in the results.</span></p></blockquote><h4><span><strong>Additional Analyses</strong></span></h4><h5><span><strong>Raw Data</strong></span></h5><ul><li><span>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</span></li></ul><h5><span><strong>Fentanyl Presence Analysis</strong></span></h5><h5><span><strong>Variance Testing</strong></span></h5><ul><li><span>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</span></li></ul><h5><span><strong>pH Measurement</strong></span></h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522"><span><strong>Endotoxin Analysis</strong></span></a></h5><ul><li><span>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</span></li><li><span>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</span></li><li><span>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</span></li></ul><h5><span><strong>Additional Report</strong></span></h5><ul><li><span>A separate additional laboratory report issued under a different client name.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><span><strong>LC-MS Screening for Peptide Contamination</strong></span></a></h5><ul><li><span>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</span></li><li><span>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527"><span><strong>Sterility Testing</strong></span></a></h5><ul><li><span>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</span></li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><span><strong>Heavy Metals Analysis</strong></span></a></h5><ul><li><span>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</span></li></ul>

Enclomiphene analysis

Targeted HPLC analysis of enclomiphene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

<p><strong>The Enclomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of enclomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.</strong></p><p>The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).</p><h4><strong>About Enclomiphene&nbsp;</strong></h4><p>Enclomiphene is the trans-isomer of clomiphene and is classified as a non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can reduce estrogen-mediated negative feedback within the hypothalamic–pituitary–gonadal axis, thereby influencing the secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH).</p><p>Enclomiphene has been investigated in clinical studies focused primarily on hormonal regulation and testosterone levels in men with secondary hypogonadism.</p><h4><strong>Key Features</strong></h4><ul><li>Targeted identification and quantification of enclomiphene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4><strong>Analysis Parameters</strong></h4><ul><li><strong>Target compound:</strong> Enclomiphene</li><li><strong>CAS number: </strong>15690-57-0</li><li><strong>Testing method: </strong>HPLC</li><li><strong>Minimum amount of target compound for evaluation in oral products:</strong> 5 mg per pill, tablet, or capsule</li><li><strong>Minimum content of target compound for evaluation in raw API powders: </strong>10%</li><li><strong>Result format for oral products:</strong> mg per tablet or capsule</li><li><strong>Result format for raw API powders:</strong> % [98%+, 96%+ or % value such as 94.15%]</li><li><strong>Minimum sample amount for oral products:</strong> Three tablets or capsules</li><li><strong>Minimum sample amount for raw API powders:</strong> 200 mg</li><li><strong>Average turnaround time:</strong> 7 business days</li></ul><blockquote><p><strong>Important Notice</strong></p><ul><li>This analysis is specifically intended for enclomiphene. It does not automatically screen the sample for clomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of enclomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4><strong>Optional Additional Analyses</strong></h4><p>The following optional laboratory services are available:</p><ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524"><strong>GC–MS Contamination Screening</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525"><strong>Heavy Metals Analysis (As, Cd, Pb, Hg)</strong></a></li><li>Additional Laboratory Report</li></ul>

Products focused on HPLC - page 10

Related content

Comprehensive investigation of matrix effect evaluation approaches for reliable quantification in bioanalysis using UHPLC-MS/MS

ISC 2026 - Day 4

Webinars LabRulezLCMS Week 38/2026